NCT00022932View on ClinicalTrials.gov

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

PHASE2UnknownINTERVENTIONAL
Timeline

Start Date

January 31, 2000

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Iodine-131 Anti-B1 Antibody

Trial Locations (3)

10021

Cornell Medical Center, New York

60612

Rush Medical Center, Chicago

02111

Tufts New England Medical Center, Boston

Sponsors

Lead Sponsor

Corixa Corporation
All Listed Sponsors
lead

Corixa Corporation

INDUSTRY

NCT00022932 - Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP | Biotech Hunter | Biotech Hunter